1/16
12:28 pm
pvla
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $192.00 price target on the stock.
Low
Report
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $192.00 price target on the stock.
1/12
06:12 am
pvla
Assessing Palvella Therapeutics (PVLA) Valuation After Strong One Year Returns And Conflicting Signals [Yahoo! Finance]
Medium
Report
Assessing Palvella Therapeutics (PVLA) Valuation After Strong One Year Returns And Conflicting Signals [Yahoo! Finance]
1/9
09:17 am
pvla
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies [Yahoo! Finance]
Medium
Report
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies [Yahoo! Finance]
1/9
07:30 am
pvla
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies
Medium
Report
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies
1/7
08:02 am
pvla
Palvella Therapeutics (NASDAQ:PVLA) is now covered by analysts at Mizuho. They set an "outperform" rating and a $205.00 price target on the stock.
Medium
Report
Palvella Therapeutics (NASDAQ:PVLA) is now covered by analysts at Mizuho. They set an "outperform" rating and a $205.00 price target on the stock.
1/7
07:30 am
pvla
Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs
Medium
Report
Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs
12/23
10:44 am
pvla
Palvella Therapeutics: Phase 2 Success De-Risks 2026 Catalyst [Seeking Alpha]
Medium
Report
Palvella Therapeutics: Phase 2 Success De-Risks 2026 Catalyst [Seeking Alpha]
12/21
07:42 am
pvla
High Analyst Confidence on Palvella Therapeutics (PVLA) Following Encouraging Phase 2 Data for QTORIN Rapamycin [Yahoo! Finance]
Medium
Report
High Analyst Confidence on Palvella Therapeutics (PVLA) Following Encouraging Phase 2 Data for QTORIN Rapamycin [Yahoo! Finance]
12/20
09:41 pm
pvla
Assessing Palvella Therapeutics' Valuation After Its Rare Disease Momentum-Driven Surge in 2024 [Yahoo! Finance]
Medium
Report
Assessing Palvella Therapeutics' Valuation After Its Rare Disease Momentum-Driven Surge in 2024 [Yahoo! Finance]
12/16
10:55 am
pvla
Palvella Therapeutics price target raised to $200 from $120 at Oppenheimer [Yahoo! Finance]
Medium
Report
Palvella Therapeutics price target raised to $200 from $120 at Oppenheimer [Yahoo! Finance]
12/16
09:11 am
pvla
Palvella Therapeutics (NASDAQ:PVLA) was given a new $204.00 price target on by analysts at Canaccord Genuity Group Inc..
Medium
Report
Palvella Therapeutics (NASDAQ:PVLA) was given a new $204.00 price target on by analysts at Canaccord Genuity Group Inc..
12/16
09:08 am
pvla
Palvella Therapeutics (NASDAQ:PVLA) had its price target raised by analysts at TD Cowen from $97.00 to $133.00. They now have a "buy" rating on the stock.
Medium
Report
Palvella Therapeutics (NASDAQ:PVLA) had its price target raised by analysts at TD Cowen from $97.00 to $133.00. They now have a "buy" rating on the stock.
12/16
08:43 am
pvla
Palvella Therapeutics (NASDAQ:PVLA) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc..
Medium
Report
Palvella Therapeutics (NASDAQ:PVLA) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc..
12/16
08:04 am
pvla
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Medium
Report
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at Cowen Inc.
12/16
07:30 am
pvla
Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Angiokeratomas
Medium
Report
Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Angiokeratomas
12/15
07:02 pm
pvla
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at BTIG Research.
Medium
Report
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at BTIG Research.
12/15
07:01 pm
pvla
Palvella Therapeutics (NASDAQ:PVLA) was given a new $174.00 price target on by analysts at Chardan Capital.
Medium
Report
Palvella Therapeutics (NASDAQ:PVLA) was given a new $174.00 price target on by analysts at Chardan Capital.
12/15
04:05 pm
pvla
Palvella Therapeutics (NASDAQ:PVLA) was given a new $190.00 price target on by analysts at Truist Financial Corporation.
Medium
Report
Palvella Therapeutics (NASDAQ:PVLA) was given a new $190.00 price target on by analysts at Truist Financial Corporation.
12/15
03:05 pm
pvla
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Low
Report
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at UBS Group AG.
12/15
02:05 pm
pvla
Palvella Therapeutics (NASDAQ:PVLA) was given a new $200.00 price target on by analysts at HC Wainwright.
Low
Report
Palvella Therapeutics (NASDAQ:PVLA) was given a new $200.00 price target on by analysts at HC Wainwright.
12/15
11:08 am
pvla
Palvella Therapeutics (NASDAQ:PVLA) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Low
Report
Palvella Therapeutics (NASDAQ:PVLA) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
12/15
06:15 am
pvla
Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approve
High
Report
Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approve
12/15
06:00 am
pvla
Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approve
High
Report
Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approve
12/11
10:04 am
pvla
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/10
04:10 am
pvla
Palvella Therapeutics (NASDAQ:PVLA) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Palvella Therapeutics (NASDAQ:PVLA) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.